181 related articles for article (PubMed ID: 36813172)
1. Preclinical trial comparing radiotherapy alone versus standard radiochemotherapy in three human papilloma virus (HPV) negative and three HPV-positive head and neck squamous cell carcinoma (HNSCC) xenograft tumour models.
Valentini C; Ebert N; Koi L; Pfeifer M; Löck S; Erdmann C; Krause M; Baumann M
Radiother Oncol; 2023 Jun; 183():109546. PubMed ID: 36813172
[TBL] [Abstract][Full Text] [Related]
2. EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation.
Alsahafi EN; Thavaraj S; Sarvestani N; Novoplansky O; Elkabets M; Ayaz B; Tavassoli M; Legends MF
Cancer Lett; 2021 Feb; 498():80-97. PubMed ID: 33137407
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus associated XPF deficiency increases alternative end joining and cisplatin sensitivity in head and neck squamous cell carcinoma.
Zuo N; Ma L; Liu T; Hu W; Luo Y; Meng H; Ren Q; Deng Y; Wei L; Liu Q
Oral Oncol; 2023 May; 140():106367. PubMed ID: 36996606
[TBL] [Abstract][Full Text] [Related]
4. Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal.
Huang SH; O'Sullivan B; Su J; Ringash J; Bratman SV; Kim J; Hosni A; Bayley A; Cho J; Giuliani M; Hope A; Spreafico A; Hansen AR; Siu LL; Gilbert R; Irish JC; Goldstein D; de Almeida J; Tong L; Xu W; Waldron J
Cancer; 2020 Aug; 126(15):3426-3437. PubMed ID: 32478895
[TBL] [Abstract][Full Text] [Related]
5. Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer.
de Roest RH; van der Heijden M; Wesseling FWR; de Ruiter EJ; Heymans MW; Terhaard C; Vergeer MR; Buter J; Devriese LA; de Boer JP; Navran A; Hoeben A; Vens C; van den Brekel M; Brakenhoff RH; Leemans CR; Hoebers F
Radiother Oncol; 2022 Oct; 175():112-121. PubMed ID: 35973619
[TBL] [Abstract][Full Text] [Related]
6. Radiotherapy combined with docetaxel alters the immune phenotype of HNSCC cells and results in increased surface expression of CD137 and release of HMGB1 of specifically HPV-positive tumor cells.
Grottker F; Gehre S; Reichardt CM; Sengedorj A; Jost T; Rieckmann T; Hecht M; Gostian AO; Frey B; Fietkau R; Gaipl US; Rückert M
Neoplasia; 2023 Nov; 45():100944. PubMed ID: 37857049
[TBL] [Abstract][Full Text] [Related]
7. Prognostic biomarkers for the response to the radiosensitizer nimorazole combined with RCTx: a pre-clinical trial in HNSCC xenografts.
Koi L; Bitto V; Weise C; Möbius L; Linge A; Löck S; Yaromina A; Besso MJ; Valentini C; Pfeifer M; Overgaard J; Zips D; Kurth I; Krause M; Baumann M
J Transl Med; 2023 Aug; 21(1):576. PubMed ID: 37633930
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic implications of transcriptomics in head and neck cancer patient-derived xenografts.
Lee RH; Roy R; Li H; Hechmer A; Zhu TR; Izgutdina A; Olshen AB; Johnson DE; Grandis JR
PLoS One; 2023; 18(3):e0282177. PubMed ID: 36857322
[TBL] [Abstract][Full Text] [Related]
9. Computed Tomography Radiomics Predicts HPV Status and Local Tumor Control After Definitive Radiochemotherapy in Head and Neck Squamous Cell Carcinoma.
Bogowicz M; Riesterer O; Ikenberg K; Stieb S; Moch H; Studer G; Guckenberger M; Tanadini-Lang S
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):921-928. PubMed ID: 28807534
[TBL] [Abstract][Full Text] [Related]
10. Palbociclib-based high-throughput combination drug screening identifies synergistic therapeutic options in HPV-negative head and neck squamous cell carcinoma.
Gu Z; Shi C; Li J; Han Y; Sun B; Zhang W; Wu J; Zhou G; Ye W; Li J; Zhang Z; Zhou R
BMC Med; 2022 May; 20(1):175. PubMed ID: 35546399
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Evaluation of the ATR Inhibitor BAY 1895344 as a Radiosensitizer for Head and Neck Squamous Cell Carcinoma.
Odhiambo DA; Pittman AN; Rickard AG; Castillo RJ; Bassil AM; Chen J; Ravotti ML; Xu ES; Himes JE; Daniel AR; Watts TL; Williams NT; Luo L; Kirsch DG; Mowery YM
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1315-1327. PubMed ID: 38104870
[TBL] [Abstract][Full Text] [Related]
12. EGFR-amplification plus gene expression profiling predicts response to combined radiotherapy with EGFR-inhibition: A preclinical trial in 10 HNSCC-tumour-xenograft models.
Koi L; Löck S; Linge A; Thurow C; Hering S; Baumann M; Krause M; Gurtner K
Radiother Oncol; 2017 Sep; 124(3):496-503. PubMed ID: 28807520
[TBL] [Abstract][Full Text] [Related]
13. The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.
Hagege A; Ambrosetti D; Boyer J; Bozec A; Doyen J; Chamorey E; He X; Bourget I; Rousset J; Saada E; Rastoin O; Parola J; Luciano F; Cao Y; Pagès G; Dufies M
Theranostics; 2021; 11(19):9571-9586. PubMed ID: 34646387
[No Abstract] [Full Text] [Related]
14. Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer.
Ferris RL; Geiger JL; Trivedi S; Schmitt NC; Heron DE; Johnson JT; Kim S; Duvvuri U; Clump DA; Bauman JE; Ohr JP; Gooding WE; Argiris A
Ann Oncol; 2016 Dec; 27(12):2257-2262. PubMed ID: 27733374
[TBL] [Abstract][Full Text] [Related]
15. nab-Paclitaxel-based induction chemotherapy followed by cisplatin and radiation therapy for human papillomavirus-unrelated head and neck squamous-cell carcinoma.
Johnson KCC; Ley J; Oppelt P; Lu J; Gay HA; Daly M; Jackson R; Rich J; Pipkorn P; Paniello RC; Zevallos J; Thorstad W; Adkins DR
Med Oncol; 2019 Oct; 36(11):93. PubMed ID: 31595355
[TBL] [Abstract][Full Text] [Related]
16. Concurrent weekly cisplatin and simultaneous integrated boost intensity-modulated radiotherapy of locally advanced squamous cell carcinoma of the head and neck.
Dubinský P; Jeremic B; Švajdová M; Barilíková G; Matula P; Nadzonová D; Vojtek V
Klin Onkol; 2022; 35(4):307-314. PubMed ID: 35989088
[TBL] [Abstract][Full Text] [Related]
17. ATR inhibition sensitizes HPV
Leonard BC; Lee ED; Bhola NE; Li H; Sogaard KK; Bakkenist CJ; Grandis JR; Johnson DE
Oral Oncol; 2019 Aug; 95():35-42. PubMed ID: 31345392
[TBL] [Abstract][Full Text] [Related]
18. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus-associated head and neck squamous cell carcinoma survival: a comparison by tumor site and initial treatment.
Salazar CR; Smith RV; Garg MK; Haigentz M; Schiff BA; Kawachi N; Anayannis N; Belbin TJ; Prystowsky MB; Burk RD; Schlecht NF
Head Neck Pathol; 2014 Mar; 8(1):77-87. PubMed ID: 24002971
[TBL] [Abstract][Full Text] [Related]
20. Dynamic changes of the EMT spectrum between circulating tumor cells and the tumor microenvironment in human papillomavirus-positive head and neck squamous cell carcinoma.
Ida S; Takahashi H; Tada H; Mito I; Matsuyama T; Chikamatsu K
Oral Oncol; 2023 Feb; 137():106296. PubMed ID: 36571985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
